Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.67 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.67 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.67 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.67 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.67 |
| ▸ | HTR2A | P28223 | 1/20 | 0.64 |
| ▸ | HTR1A | P08908 | 3/20 | 0.60 |
| ▸ | DRD2 | P14416 | 3/20 | 0.58 |
| ▸ | DRD3 | P35462 | 3/20 | 0.58 |
| ▸ | DRD4 | P21917 | 2/20 | 0.58 |
| ▸ | DRD1 | P21728 | 1/20 | 0.58 |
| ▸ | DRD5 | P21918 | 1/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | BCHE | P06276 | 2/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.52 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11545434 | 0.85 | HTR2A (0.67) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL6465788 | 0.84 | HTR2A (0.88) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL11544611 | 0.83 | ADRA2A (0.68) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL11474850 | 0.83 | ADRA2A (0.74) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL9033591 | 0.83 | DRD2 (0.56) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL24746503 | 0.82 | HTR2A (0.74) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL11333398 | 0.81 | DRD2 (0.76) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL11461252 | 0.81 | ADRA2A (0.65) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL5339006 | 0.81 | DRD2 (0.75) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL7954617 | 0.81 | HTR2A (0.72) | ADRA2AADRA2BADRA2CADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2144503-B9 | 4-(octahydro-2H-isoindol-2-yl)-1,3-oxazol-4-one as TACHYKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-09-04 | — | — | EP | disclosed |
| EP-2144503-B1 | 4-(octahydro-2H-isoindol-2-yl)-1,3-oxazol-4-one as TACHYKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-03-27 | — | — | EP | disclosed |
| US-8124633-B2 | Hydroxymethyl ether hydroisoindoline tachykinin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100197724-A1 | 6.5 -PYRROLOPIPERIDINE TACHYKININ RECEPTOR ANTAGONISTS | BAO JIANMING | 2010-08-05 | — | — | US | disclosed |
| US-20100113469-A1 | COMBINATION THERAPY FOR THE TREATMENT-OF LOWER URINARY TRACT SYMPTOMS | MERCK & CO., INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100105747-A1 | HYDROXYMETHYL ETHER HYDROISOINDOLINE TACHYKININ RECEPTOR ANTAGONISTS | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2010-04-29 | — | — | US | disclosed |
| EP-2144503-A1 | HYDROXYMETHYL ETHER HYDROISOINDOLINE TACHYKININ RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2010-01-20 | — | — | EP | disclosed |
| EP-2141992-A1 | COMBINATION THERAPY FOR THE TREATMENT-OF LOWER URINARY TRACT SYMPTOMS | Merck & Co., Inc. (US) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008124143-A1 | HYDROXYMETHYL ETHER HYDROISOINDOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008121268-A1 | COMBINATION THERAPY FOR THE TREATMENT-OF LOWER URINARY TRACT SYMPTOMS | MERCK & CO., INC. (US) | 2008-10-09 | — | — | WO | disclosed |
| WO-1994011386-A1 | 17-ALPHA AND 17-BETA SUBSTITUTED ACYL-3-CARBOXY-3,5-DIENES AND USE IN INHIBITING 5-ALPHA-REDUCTASE | SMITHKLINE BEECHAM CORPORATION (US) | 1994-05-26 | — | — | WO | disclosed |
| WO-1994011385-A1 | 17-ALPHA-ACYL STEROIDS WHICH INHIBIT 5-ALPHA-REDUCTASE | SMITHKLINE BEECHAM CORPORATION (US) | 1994-05-26 | — | — | WO | disclosed |
| WO-1994011004-A1 | 17 SUBSTITUTED ACYL-3-CARBOXY 3,5-DIENE STEROIDALS AS 5-ALPHA-REDUCTASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-05-26 | — | — | WO | disclosed |
| WO-1994000121-A1 | 17-ACYL-4-AZA-STEROID-3-ONE AS 5-ALPHA-REDUCTASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-01-06 | — | — | WO | disclosed |
| WO-1994000125-A1 | 17-ALKYLKETONE STEROIDS USEFUL AS 5-α-REDUCTASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-01-06 | — | — | WO | disclosed |
| WO-1993023042-A1 | 17α AND 17β SUBSTITUTED ACYL 4 AZA STEROIDS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-11-25 | — | — | WO | disclosed |
| WO-1993022333-A1 | 17α AND 17β-SUBSTITUTED ESTRA-1,3,5(10)-TRIENE-3-CARBOXYLIC ACID | SMITHKLINE BEECHAM CORPORATION (US) | 1993-11-11 | — | — | WO | disclosed |
| WO-1993019758-A1 | COMPOSITIONS AND METHODS FOR TREATING BENIGN PROSTATIC HYPERTROPHY | SMITHKLINE BEECHAM CORPORATION (US) | 1993-10-14 | — | — | WO | disclosed |
| EP-0067539-B1 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION | JOHN WYETH & BROTHER LIMITED (GB) | 1985-09-18 | — | — | EP | disclosed |
| EP-0154553-A2 | Use of compounds for increasing plasma high density lipoprotein cholesterol | JOHN WYETH & BROTHER LIMITED (GB) | 1985-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113469-A1 | COMBINATION THERAPY FOR THE TREATMENT-OF LOWER URINARY TRACT SYMPTOMS | KLK5, ADRB1, ADRB3 | ADRA2A 18/4885ADRA2B 14/4885ADRA2C 21/4885 |
| US-20100105747-A1 | HYDROXYMETHYL ETHER HYDROISOINDOLINE TACHYKININ RECEPTOR ANTAGONISTS | TACR1, HTR1D, TACR2 | ADRA2A 254/4885ADRA2B 325/4885ADRA2C 217/4885 |
| US-20100197724-A1 | 6.5 -PYRROLOPIPERIDINE TACHYKININ RECEPTOR ANTAGONISTS | TACR1, TACR2, HTR1D | ADRA2A 364/4885ADRA2B 549/4885ADRA2C 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.